Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 139 CLL GIVE trial: obinutuzumab + venetoclax with standard vs MRD-guided maintenance in first-line unfit CLL
2024-511048-22-00Phase 2Completed
- Sponsor
- HOVON
- Start
- May 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of obinutuzumab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by HOVON. Primary endpoint: Bone marrow MRD negativity. Started May 2024; status: completed.
02
Drugs
obinutuzumabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-511048-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511048-22-00.